ライフサイエンスコーパス: periodontal therapy

1 esponse in LAP can be partially modulated by periodontal therapy.

2 ity of periodontal disease and the effect of periodontal therapy.

3 and six oral antibiotics of potential use in periodontal therapy.

4 critical to optimize the results of surgical periodontal therapy.

5 otics are emerging as a promising adjunctive periodontal therapy.

6 t and control sites as an adjunct to Phase 1 periodontal therapy.

7 (n = 20) included patients who did not have periodontal therapy.

8 eatment of intrabony defects during surgical periodontal therapy.

9 essure and subclinical atherosclerosis after periodontal therapy.

10 Serum analytes were not influenced by periodontal therapy.

11 raphic indicators of bone regeneration after periodontal therapy.

12 matrix derivative (EMD) is commonly used in periodontal therapy.

13 before and after completion of non-surgical periodontal therapy.

14 of D-ROM (P < 0.01) were observed following periodontal therapy.

15 nd did not undergo resective or regenerative periodontal therapy.

16 enzyme inhibitors or receptor antagonists in periodontal therapy.

17 loss, are the actual and desired outcomes of periodontal therapy.

18 icient calculus removal is a primary goal in periodontal therapy.

19 s in practice, and referral for non-surgical periodontal therapy.

20 f depression on their patients' responses to periodontal therapy.

21 s remaining after completion of non-surgical periodontal therapy.

22 ma denticola before and following mechanical periodontal therapy.

23 n patients usually not receiving concomitant periodontal therapy.

24 CAL, or BOP 2 years after completion of the periodontal therapy.

25 cerns about medications as a risk factor for periodontal therapy.

26 ion of migrated teeth sometimes occurs after periodontal therapy.

27 is often the motivation for patients to seek periodontal therapy.

28 delivery of a standard non-surgical phase of periodontal therapy.

29 attachment compared to non-smokers following periodontal therapy.

30 ts represents a unique treatment approach in periodontal therapy.

31 ts to be initially treated with non-surgical periodontal therapy.

32 mos after delivery of standard non-surgical periodontal therapy.

33 trends in referral patterns of patients for periodontal therapy.

34 tigated further for possible development for periodontal therapy.

35 monitored before and up to 5 years following periodontal therapy.

36 le-dose drug delivery systems appropriate to periodontal therapy.

37 to and at 3, 6, 12, 24, and 36 months after periodontal therapy.

38 in assessing disease status and response to periodontal therapy.

39 teroid therapy as an adjunct to non-surgical periodontal therapy.

40 regard it as osteoinductive when utilized in periodontal therapy.

41 odontal healing in barrier membrane-assisted periodontal therapy.

42 th EB present a unique challenge in terms of periodontal therapy.

43 urgical treatment and a period of supportive periodontal therapy.

44 inical outcomes of non-surgical and surgical periodontal therapy.

45 uate the effect of smoking on the outcome of periodontal therapy.

46 ant role in achieving a desirable outcome in periodontal therapy.

47 ing used clinically than any other agents in periodontal therapy.

48 ccess needs after completion of non-surgical periodontal therapy.

49 of 134 patients were screened 10 years after periodontal therapy.

50 al disease in smokers remains a challenge of periodontal therapy.

51 of statins or bisphosphonates as adjuncts to periodontal therapy.

52 acebo capsules as an adjunct to conservative periodontal therapy.

53 ows the efficacy of platelet concentrates in periodontal therapy.

54 ividuals that respond poorly to conventional periodontal therapy.

55 emains poorly investigated in the context of periodontal therapy.

56 ) would enhance the outcomes of non-surgical periodontal therapy.

57 lent alternative for dentists in nonsurgical periodontal therapy.

58 mise as a diagnostic and therapeutic tool in periodontal therapy.

59 ment of gingival condition and changes after periodontal therapy.

60 periodontitis before and after non-surgical periodontal therapy.

61 ATV or placebo gels as adjunct to mechanical periodontal therapy.

62 e of Gram-negative bacteria before and after periodontal therapy.

63 periodontitis were treated with non-surgical periodontal therapy.

64 Periodontitis patients received non-surgical periodontal therapy.

65 patients are more compliant with supportive periodontal therapy.

66 line and at the first and third months after periodontal therapy.

67 of furcation defects is a core component of periodontal therapy.

68 djunct to resective or regenerative surgical periodontal therapy.

69 defects is an important therapeutic goal of periodontal therapy.

70 ver (FMF) and their response to non-surgical periodontal therapy.

71 quires effective endodontic and regenerative periodontal therapy.

72 onization of flora may affect the outcome of periodontal therapy.

73 tool for calculus detection in non-surgical periodontal therapy.

74 -1 genotypes on the outcomes of non-surgical periodontal therapy.

75 periodontitis before and after non-surgical periodontal therapy.

76 erapy (PDT) as monotherapy during supportive periodontal therapy.

77 tors of poor response following non-surgical periodontal therapy.

78 at baseline and 3 months after non-surgical periodontal therapy.

79 received an intensive course of non-surgical periodontal therapy.

80 on periodontitis progression and response to periodontal therapy.

81 nts responding poorly to mechanical forms of periodontal therapy.

82 t was treated with non-surgical and surgical periodontal therapies.

83 iscuss strategies for future applications in periodontal therapies.

84 is, randomly assigned into test group (basic periodontal therapy + 0.12% chlorhexidine) with 61 impla

85 cations used after surgical and non-surgical periodontal therapy (4-week period).

86 d to either (a) one-time, shortened outreach periodontal therapy adapted to German statutory health g

87 ects with above average clinical response to periodontal therapy after correction for possible confou

88 or alveolar bone compared with conventional periodontal therapy alone.

89 ficantly reduced 3 months after non-surgical periodontal therapy, although they never reached the sam

90 ation lesions are a challenging scenario for periodontal therapy and a serious threat for tooth progn

91 mination and PRA were performed after active periodontal therapy and after 3 years of PMT.

92 rous and insightful look into the origins of periodontal therapy and anesthesia in "Happy Memories of

93 ria reduction process, it was suggested that periodontal therapy and chlorhexidine (CHX) rinse could

94 dontal disease before and after non-surgical periodontal therapy and correlate these values with clin

95 mproves the clinical outcome of non-surgical periodontal therapy and may be an appropriate adjunctive

96 dy is to evaluate the effect of non-surgical periodontal therapy and medical treatment on the level o

97 Healing following initial periodontal therapy and osseous periodontal surgery occu

98 Non-surgical periodontal therapy and periodontal disease severity wer

99 Smokers have a diminished response to periodontal therapy and show approximately half as much

100 Following nonsurgical periodontal therapy and smoking cessation, the subgingiv

101 uence cytokine expression after non-surgical periodontal therapy and supportive periodontal care.

102 iologic effects of a two-phase antimicrobial periodontal therapy and tested microbiologic, clinical,

103 Patients with GAgP received non-surgical periodontal therapy and were followed for 6 months.

104 aluated at two time points: T1 (after active periodontal therapy) and T2 (6 years).

105 two instances: T1 (first time, after active periodontal therapy) and T2 (second time, 6 years).

106 vercome limitations associated with existing periodontal therapies, and may provide a new direction i

107 nce of periodontal disease, poor response to periodontal therapy, and a high risk for developing head

108 ical and radiographic response to mechanical periodontal therapy, and assess the factors associated w

109 etween host-parasite interaction, outcome of periodontal therapy, and systemic factors is best repres

110 erties of tetracycline (TCN) are valuable in periodontal therapy, and TCN treatment can remove the sm

111 Care include tobacco cessation as a part of periodontal therapy, and the 2000 Surgeon General's Repo

112 pathologically migrated teeth after routine periodontal therapy, and to study the relation between t

113 ation involvement; non-surgical and surgical periodontal therapy; and reasons for tooth loss.

114 Periodontal treatment consists of active periodontal therapy (APT) and supportive periodontal the

115 postoperative care and subsequent supportive periodontal therapy are essential to achieve sustainable

116 ied bone allograft (DFDBA) is widely used in periodontal therapy as a scaffold for new bone formation

117 Tetracyclines are used in periodontal therapy as antimicrobial agents and as inhib

118 Ts) consistently demonstrate that mechanical periodontal therapy associates with approximately a 0.4%

119 xidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months.

120 enhance the effectiveness of these agents in periodontal therapy by enhancing or sustaining their the

121 chronic periodontitis receiving non-surgical periodontal therapy by SRP with (test) and without (cont

122 itis (good responders [GR]) before and after periodontal therapy by using the Human Oral Microbe Iden

123 Information on sociodemographics, periodontal therapy, calculus and plaque, number of rema

124 It also suggests that periodontal therapy can be performed successfully at sit

125 ng the level of PGRN in GCF before and after periodontal therapy could in the future be useful for pe

126 vious studies have suggested that success of periodontal therapy depends on the specific attachment,

127 Nonsurgical periodontal therapy did not improve glycemic control in

128 The NPC appreciates that periodontal therapy done by periodontists increases thei

129 tion with the use of lasers for non-surgical periodontal therapy due to ablation, vaporization, hemos

130 ontal Therapy [OPT] Study) demonstrated that periodontal therapy during pregnancy improved periodonta

131 ffect of intensive oral hygiene regimens and periodontal therapy during pregnancy on periodontal heal

132 Periodontal therapy during the second trimester improves

133 minimum 12 months) with CP with non-surgical periodontal therapy either alone or associated with loca

134 In periodontal therapy enamel matrix derivative (EMD) has b

135 Regenerative periodontal therapy encompasses use of various bioactive

136 d better compliance than those without prior periodontal therapy experiences.

137 indings from interventional studies in which periodontal therapy failed to alleviate systemic health

138 atients were treated with four modalities of periodontal therapy followed by supportive periodontal t

139 eatment and after completion of non-surgical periodontal therapy for 213 sextants in 38 patients by t

140 ived oral hygiene instruction and mechanical periodontal therapy for a period of 4 to 5 weeks.

141 Published RCTs including periodontal therapy for diabetic subjects, a metabolic o

142 Decisions in periodontal therapy for multirooted teeth are essentiall

143 cal role for smoking cessation counseling in periodontal therapy for smokers in order to effectively

144 uld improve clinical results of non-surgical periodontal therapy for smokers with chronic periodontit

145 of Glanzmann's thrombasthenia presented for periodontal therapy for spontaneous gingival hemorrhage.

146 ients who received non-surgical and surgical periodontal therapy from 1966 to 2007.

147 At 6 months, mean HbA1c levels in the periodontal therapy group increased 0.17% (SD, 1.0), com

148 terns of SAEs indicated that subjects in the periodontal therapy group tended to be less likely to ex

149 Non-surgical periodontal therapy had a beneficial effect on the signs

150 Although periodontal therapy has been shown to be safe and leads

151 However, its influence on periodontal therapy has not been clearly determined.

152 sive techniques in non-surgical and surgical periodontal therapy has not progressed to the same exten

153 namel matrix protein derivative (EMD) during periodontal therapy have been shown to be safe for the p

154 growing interest in the use of probiotics in periodontal therapy; however, until now, most research h

155 Periodontal therapy improved clinical and microbiologic

156 Likewise, recent non-smokers respond to periodontal therapy in a manner similar to patients who

157 nhance the clinical benefits of non-surgical periodontal therapy in adults who are otherwise healthy.

158 In this context, the support of nonsurgical periodontal therapy in diabetics with host modulation ag

159 s would improve the response to non-surgical periodontal therapy in obese patients.

160 e to conduct a secondary prevention trial of periodontal therapy in patients who have had coronary he

161 biotic supplementation adjunctive to initial periodontal therapy in patients with chronic periodontit

162 Initial periodontal therapy in patients with COPD with CP may de

163 10, 1 month, and 3 months following initial periodontal therapy in patients with CP.

164 on clinical response following non-surgical periodontal therapy in patients with severe periodontiti

165 polymorphisms are associated with success of periodontal therapy in pregnant women with periodontal d

166 e evidence suggesting a negligible effect of periodontal therapy in reducing interleukin-6 and lipids

167 microbials improved efficacy of non-surgical periodontal therapy in reducing PD and improving CAL at

168 th SRP improves the efficacy of non-surgical periodontal therapy in reducing probing depth and improv

169 t reduction in HbA1c observed as a result of periodontal therapy in subjects with type 2 diabetes is

170 statistically significant improvement after periodontal therapy in the BS compared with the obese gr

171 nct to SRP to provide a new dimension in the periodontal therapy in the near future.

172 This report proves the efficiency of periodontal therapy in the prevention of future periodon

173 ary or even justified to evaluate effects of periodontal therapy in these defects, and can be substit

174 rant secretion of chemerin, and non-surgical periodontal therapy influenced the decrease of GCF cheme

175 it mouth study evaluated a new model to test periodontal therapy involving a novel bioerodible copoly

176 d the impact of standard (SPT) and intensive periodontal therapy (IPT) on serum inflammatory markers

177 ological response of smokers to non-surgical periodontal therapy is compared to non-smokers.

178 Long-term evaluation of periodontal therapy is important for clinical decision m

179 tion of whether the additional use of EMD in periodontal therapy is more effective compared with a co

180 An improved response to non-surgical periodontal therapy is observed in obese patients who ha

181 lized freeze-dried bone allograft (DFDBA) in periodontal therapy is widely accepted.

182 Mechanical periodontal therapy is widely used for a variety of peri

183 modulation of host inflammatory response in periodontal therapy, it is important to control the bact

184 Additionally, periodontal therapy led to a parallel reduction in the s

185 of patients with periodontitis submitted to periodontal therapy/maintenance and implant placement.

186 These findings suggest that non-surgical periodontal therapy may be associated with a substantial

187 Initial periodontal therapy may be helpful for diminishing oxida

188 ies suggest that initial patient response to periodontal therapy may be related to emotional intellig

189 Limited evidence suggests that periodontal therapy may improve glycemic control.

190 Thus, while periodontal therapy may improve oral health, it may be e

191 The current study investigates whether periodontal therapy may reduce systemic inflammation in

192 Periodontal therapy may reduce these pathogens colonized

193 and oral hygiene instructions (n = 20) or no periodontal therapy (n = 20).

194 ed randomly to either a control group (C; no periodontal therapy) (n = 35) or an experimental group (

195 ilure or success 5 years after completion of periodontal therapy, none of the four strategies produce

196 root sensitivity (RS) following non-surgical periodontal therapy (NSPT) is limited.

197 tudy investigated the impact of non-surgical periodontal therapy (NSPT) on clinical and immunological

198 ssess the short-term effects of non-surgical periodontal therapy (NSPT) on the gingival crevicular fl

199 After non-surgical periodontal therapy (NSPT), test sites received Nd:YAG l

200 After non-surgical periodontal therapy (NSPT), test sites received Nd:YAG l

201 n terms of healing duration post nonsurgical periodontal therapy (NSPT).

202 cal biofilm disruption known as non-surgical periodontal therapy (NSPT).

203 d to evaluate the changes after non-surgical periodontal therapy (NSPT).

204 effective adjuvant treatments to nonsurgical periodontal therapy offering strong antiresorptive prope

205 in-1, (b) limited evidence on the effects of periodontal therapy on arterial blood pressure, leucocyt

206 zithromycin in combination with non-surgical periodontal therapy on clinical and microbiologic parame

207 The effect of periodontal therapy on diabetes outcomes has not been es

208 authors aim to assess the effect of initial periodontal therapy on exacerbation frequency in COPD pa

209 ; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels.

210 dy was to examine the effect of non-surgical periodontal therapy on GCF levels of ICTP and IL-1.

211 vidence is available regarding the effect of periodontal therapy on major disease endpoints such as t

212 ect of two modes of delivery of non-surgical periodontal therapy on patient experience of pain and or

213 eriod of 6 months the effect of non-surgical periodontal therapy on serum levels of high-sensitivity

214 sulted in: (a) no evidence on the effects of periodontal therapy on subclinical atherosclerosis, seru

215 zed controlled trials testing the effects of periodontal therapy on systemic health outcomes were con

216 G, and to examine the effect of conservative periodontal therapy on these levels.

217 The effect of periodontal therapy on these systemic factors may be rel

218 All published trials included non-surgical periodontal therapy; only two included systemic antimicr

219 of women participating in the Obstetrics and Periodontal Therapy (OPT) Study.

220 nalyses of publicly available Obstetrics and Periodontal Therapy (OPT) trial data.

221 A recent clinical trial (Obstetrics and Periodontal Therapy [OPT] Study) demonstrated that perio

222 levels of HbA1c, FPG, and CML, and improves periodontal therapy outcome in people with DMt2 and CP.

223 th factor (PDGF) have significantly enhanced periodontal therapy outcomes with a high degree of varia

224 mmunity dental care group reported receiving periodontal therapy outside of the study.

225 on of participants in this group may receive periodontal therapy outside of the study.

226 not differ between groups or during initial periodontal therapy (P >0.05).

227 _0.54, _0.19) compared to no treatment after periodontal therapy (p < 0.0001).

228 After periodontal therapy, patients with periodontitis may sti

229 ) with 61 implants; and control group (basic periodontal therapy + placebo) with 58 implants.

230 l maintenance care, and completion of active periodontal therapy prior to October 1987.

231 levels impacted the efficacy of non-surgical periodontal therapy protocols.

232 ible participants were randomized to receive periodontal therapy provided by the study or community d

233 ied, intensive instructions and non-surgical periodontal therapy provided during 8 weeks at early pre

234 d discuss all published RCTs testing whether periodontal therapy reduces rates of preterm birth and l

235 systemic antibiotic usage, with non-surgical periodontal therapy resulted in improvement in clinical

236 lementation in conjunction with conventional periodontal therapy (scaling and root planing [SRP]) on

237 All participants received non-surgical periodontal therapy (scaling and root planing and oral h

238 All participants received non-surgical periodontal therapy (scaling and root planing).

239 fects of two different forms of non-surgical periodontal therapy, scaling and root planing (SRP) per

240 Non-surgical periodontal therapy, scaling and root planing, does not

241 Supportive periodontal therapy seemed to reduce the rate of occurre

242 Hence, regenerative periodontal therapy should be considered before resectiv

243 icillin plus metronidazole in the context of periodontal therapy should be limited to patients with s

244 In full-term and preterm women, periodontal therapy significantly reduced (P <0.01) coun

245 gnant women with periodontitis, non-surgical periodontal therapy significantly reduced levels of peri

246 lth" should be considered a true endpoint of periodontal therapy, since this outcome provides a condi

247 Following initial non-surgical periodontal therapy, sites were randomly selected to rec

248 Following non-surgical periodontal therapy, sites were randomly selected to rec

249 After periodontal therapy, sites with angular and horizontal a

250 tudy aims to assess compliance to supportive periodontal therapy (SPT) among patients treated with de

251 t the time of routinely scheduled supportive periodontal therapy (SPT) appointments by 2 evaluators.

252 Individuals enrolled in supportive periodontal therapy (SPT) can still present with tooth l

253 Patients did not receive regular supportive periodontal therapy (SPT) from 2 to 5 years post-treatme

254 Lack of supportive periodontal therapy (SPT) was shown to have nearly five-

255 in a group of patients undergoing supportive periodontal therapy (SPT).

256 ive periodontal therapy (APT) and supportive periodontal therapy (SPT).

257 Others are more useful for different periodontal therapy stages.

258 and if results are substantiated, adjunctive periodontal therapies subsequently need to be evaluated.

259 d at 3 months following completion of active periodontal therapy supplemented by amoxicillin plus met

260 study assesses the differential outcomes of periodontal therapy supplemented with amoxicillin-metron

261 and 1.5, 3, and 6 months after non-surgical periodontal therapy: supra- and subgingival plaque from

262 ays) during the first, non-surgical phase of periodontal therapy (T1) and placebo during the second,

263 rivative (EMD) as an adjunct to non-surgical periodontal therapy (test) versus non-surgical therapy a

264 Following periodontal therapy, the leukocyte activity was signific

265 onsidered the gold standard for non-surgical periodontal therapy, then the evidence supporting laser-

266 as a multicenter, randomized trial comparing periodontal therapy to community dental care.

267 to the 3-month visit, and from completion of periodontal therapy to each annual visit up to the 5-yea

268 eplacement graft (BRG) materials are used in periodontal therapy to encourage new bone formation.

269 ceutical agents has been proposed for use in periodontal therapy to inhibit loss of alveolar bone and

270 SETTING, AND PARTICIPANTS: The Diabetes and Periodontal Therapy Trial (DPTT), a 6-month, single-mask

271 ontitis who participated in the Diabetes and Periodontal Therapy Trial (DPTT); and associations among

272 Periodontal therapy triggers a short-term inflammatory r

273 ects on both hard and soft tissues following periodontal therapy using a single statistical test.

274 compare disease progression and response to periodontal therapy using both individual site activity

275 Seven patients scheduled to undergo periodontal therapy utilizing non-absorbable membranes a

276 Periodontal therapy varied considerably.

277 to assess whether the degree of response to periodontal therapy was associated with changes in serol

278 h locally and systemically, and non-surgical periodontal therapy was effective in reducing LRG levels

279 Overall, periodontal therapy was found to be effective in improvi

280 Non-surgical and surgical periodontal therapy was performed, and the patient was p

281 itis and Vascular Events (PAVE) pilot study, periodontal therapy was provided as an intervention in a

282 Periodontal therapy was successful in reducing clinical

283 urther pilot intervention study of 14 cases (periodontal therapy) was performed.

284 GCF and a significant decrease after initial periodontal therapy were determined in the CP group (P <

285 to receive immediate or delayed non-surgical periodontal therapy were evaluated at baseline and 6 mon

286 6.33 +/- 3.79 months after steps 1 and 2 of periodontal therapy were included and retrospectively an

287 oking habits and participation in supportive periodontal therapy were investigated.

288 A smoking cessation program and non-surgical periodontal therapy were offered to 80 smokers with peri

289 egeneration in smokers and non-smokers after periodontal therapy were selected.

290 All patients underwent periodontal therapy, which consisted of full-mouth mecha

291 ed to have an impact on the ultimate goal of periodontal therapy, which is tooth retention.

292 tenance program and provided with supportive periodontal therapy with 3 to 4 appointments annually.

293 Long-term microbiologic outcomes of periodontal therapy with adjunctive antibiotics either i

294 is to evaluate the influence of non-surgical periodontal therapy with adjunctive systemic antibiotics

295 bout the protocol of choice for non-surgical periodontal therapy with adjuvant use are still reported

296 review if they reported outcomes of surgical periodontal therapy with and without the use of lasers.

297 clinical treatment outcomes of regenerative periodontal therapy with bone replacement grafts.

298 mly assigned to receive initial non-surgical periodontal therapy with scaling/root planing and oral h

299 l conditions in pregnant women, case-related periodontal therapy, with or without systemic antibiotic

300 s and periodontal burden, shortened outreach periodontal therapy yielded improvements in periodontal